Roth Capital Reiterates Buy Rating for Castle Biosciences
Roth Capital continues to recommend buying Castle Biosciences with a $40 price target, a 64.61% upside from the current price.
Key Points
- Roth Capital reiterated its buy rating for Castle Biosciences, Inc. (CSTL) on June 25, 2026, with a $40 price target.
- Roth Capital's $40 price target implies 64.61% upside from Castle Biosciences, Inc.'s ($CSTL) current $24.30 share price.
- Shares of Castle Biosciences were trading at $22.12 on Thursday, with a market cap of $643 million and a 52-week range of $14.59 to $44.28.
- Insider transactions included multiple sales by CEO Derek Maetzold and COO Kristen Oelschlager in June 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Castle Biosciences, Inc. (NasdaqGM: CSTL) received a vote of confidence from Roth Capital on June 25, 2026. The firm reiterated its buy rating on the stock, setting a price target of $40. This comes as shares traded at $22.12 on Thursday.
Roth Capital vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Castle Biosciences, Inc. Stock Down 27.5%
Shares of Castle Biosciences, Inc. traded near $22.12 on Thursday. The company has a market cap of approximately $643 million. It operates with a forward P/E ratio that is not meaningful due to its lack of profitability. The stock's beta is 1.023, indicating slightly more volatility than the market. Over the past year, the stock has seen a low of $14.59 and a high of $44.28. Its 50-day moving average is $21.92, while the 200-day moving average stands at $28.71. The company maintains a strong liquidity position with a current ratio of 6.75 and a quick ratio of 6.26.
$CSTL price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Castle Biosciences reported revenue of $339.9 million, although it faced a slight decline with a revenue growth rate of -4.9%. The company is not currently profitable, with a net margin of -3.78% and a return on equity of -2.85%. Investors should mark August 3, 2026, on their calendars for the company's next earnings announcement.
Insider Buying and Selling at Castle Biosciences, Inc.
In June 2026, insider activity at Castle Biosciences included several transactions. CEO Derek Maetzold sold 4,172 shares at an average price of $20.66 on June 15 under a planned sale, while also buying 550 shares at $2.39. He made additional sales of 6,214 shares on June 1. COO Kristen Oelschlager sold 8,587 shares at $20.71 on June 16 under a Rule 10b5-1 plan.
Analysts Set New Price Targets
On June 25, 2026, Roth Capital reiterated its buy rating for Castle Biosciences with a $40 price target. BTIG also maintained a buy rating with a $40 target on May 13, 2026. Baird reiterated its buy rating on May 7, with a slightly higher target of $43. The consensus among analysts is a buy rating, with an average target price of $44 based on eight opinions.
About Castle Biosciences
Castle Biosciences, Inc. is a molecular diagnostics company based in Friendswood, Texas. It provides test solutions for dermatologic cancers, Barrett's esophagus, atopic dermatitis, and uveal melanoma. The company offers various gene expression profile tests that help predict the risk of cancer metastasis and guide treatment decisions. Led by CEO Derek J. Maetzold, Castle Biosciences serves the dermatology and gastroenterology markets.
Bottom Line
Roth Capital's reiteration of a buy rating for Castle Biosciences underscores confidence in the company's potential, despite current financial challenges. Investors should note that analyst ratings and price targets can influence stock performance, but are not guarantees. As always, 13F filings and analyst reports reflect past analyses and may not indicate future performance.
Get Castle Biosciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CSTL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.